Webcast ImageWebcast
Q1 2018 Laboratory Corporation of America Holdings Earnings Conference Call (Live)
04/25/18 at 9:00 a.m. ET
Download DocumentationLabCorp Investor & Analyst Day Presentation
E-mail Alerts Receive E-mail Alerts | RSS RSS Feeds
Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
DateTitle 
04/02/18Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021
BURLINGTON, N.C.--(BUSINESS WIRE)--Apr. 2, 2018-- LabCorp® (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below. The Zero Coupon Notes are convertible into cash and Common Stock of LabCorp, if any, subject to the terms of the Zero Coupon Notes and the Indenture, dated as of October 24, 2006, between LabCorp and The Bank of New York Mellon, as trustee... 
Printer Friendly Version
03/22/18LabCorp and Appalachian Regional Healthcare Create Comprehensive Laboratory Collaboration
LabCorp’s Expertise in Health System Collaborations will Benefit Patients across Eastern Kentucky and Southern West Virginia BURLINGTON, N.C.--(BUSINESS WIRE)--Mar. 22, 2018-- LabCorp® (NYSE: LH) and Appalachian Regional Healthcare have entered into a multi-year, comprehensive laboratory partnership. Through the collaboration, LabCorp Diagnostics will provide technical services for Appalachian Regional Healthcare’s hospital-based labs, reference test... 
Printer Friendly Version
03/12/18LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest
BURLINGTON, N.C.--(BUSINESS WIRE)--Mar. 12, 2018-- LabCorp® (NYSE: LH) announced today that for the period of March 12, 2018 to September 11, 2018, its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) will accrue (subject to the terms of the Zero Coupon Notes) contingent cash interest at a rate of no less than 0.125% of the average market price of a Zero Coupon Note for the five trading days ended March 9, 2018, in addition to the ... 
Printer Friendly Version
03/09/18Covance Forms Immunology & Immunotoxicology Unit Focused on Biologic Drug Development
Global Team Addresses the Unique Scientific Needs of Safety Assessment for Biologics BURLINGTON, N.C.--(BUSINESS WIRE)--Mar. 9, 2018-- LabCorp® (NYSE: LH), a leading global life sciences company, announced today that its Covance Drug Development (Covance) business has formed a global immunology and immunotoxicology (I&I) unit dedicated to the specific needs of biologic drug development. This team brings together Covance’s operational exper... 
Printer Friendly Version
03/07/18LabCorp is Scheduled to Present at the 2018 Barclays Global Healthcare Conference
BURLINGTON, N.C.--(BUSINESS WIRE)--Mar. 7, 2018-- LabCorp® (NYSE: LH) today announced it will participate at the 2018 Barclays Global Healthcare Conference. LabCorp’s presentation is planned for Wednesday, March 14, 2018 at 9:30 am (ET). A live audio webcast of the presentation will be available via the Company website at www.labcorp.com and archived for replay. About LabCorp LabCorp (NYSE: LH), an S&P 500 company, is a ... 
Printer Friendly Version
03/05/18LabCorp Partners with Cheeriodicals through Community Service Campaign to Florida Hospital Memorial Medical Center and Halifax Health Medical Center
DAYTONA, Fla.--(BUSINESS WIRE)--Mar. 5, 2018-- As part of a community service campaign, an enthusiastic group of LabCorp employees teamed up with Cheeriodicals to assemble and deliver 128 big green boxes to children patients at Florida Hospital Memorial Medical Center and Halifax Health Medical Center during a “Cheeriodicals Day” event held last week. Cheeriodicals are “big green boxes of cheer” made up of age-appropriate magazines and activity bo... 
Printer Friendly Version
02/28/18Covance Enters into Strategic Technology Agreement with GSK
Leverages Covance’s Xcellerate® Informatics Technology Across GSK’s Global Clinical Trials Portfolio BURLINGTON, N.C.--(BUSINESS WIRE)--Feb. 28, 2018-- LabCorp® (NYSE: LH), a leading global life sciences company, announced today that its Covance Drug Development (Covance) business has entered into a strategic technology agreement with GlaxoSmithKline plc (GSK). Under the terms of the agreement, GSK will use Covance’s Xcellerate® Monitoring, Xc... 
Printer Friendly Version
02/23/18LabCorp is Scheduled to Present at the 39th Annual Raymond James Institutional Investors Conference
BURLINGTON, N.C.--(BUSINESS WIRE)--Feb. 23, 2018-- LabCorp® (NYSE: LH) today announced it will participate at the 39th Annual Raymond James Institutional Investors Conference. LabCorp’s presentation is scheduled for Tuesday, March 6, 2018 at 8:40 AM (ET). A live audio webcast of the presentation will be available via the Company website at www.labcorp.com and archived for replay. About LabCorp LabCorp (NYSE: LH), an ... 
Printer Friendly Version
02/20/18LabCorp to Host Investor and Analyst Day on February 27, 2018
BURLINGTON, N.C.--(BUSINESS WIRE)--Feb. 20, 2018-- LabCorp® (NYSE: LH), a leading global life sciences company, will host an Investor and Analyst Day for institutional investors and financial analysts in New York City on Tuesday, February 27, 2018. The event, which will feature presentations by members of the management team, begins at 8:30 a.m. ET and will conclude by approximately 1:30 p.m. Prior registration is required to attend the event. ... 
Printer Friendly Version
02/06/18LabCorp Announces Record 2017 Fourth Quarter and Full Year Results and Provides 2018 Guidance
Net Revenue: Q4 of $2.7 billion, up 13% over 2016; Full year of $10.2 billion, up 8% over 2016 Diluted EPS: Q4 of $6.81, up 289% over 2016; Full year of $12.21, up 74% over 2016 Adjusted EPS: Q4 of $2.45, up 14% over 2016; Full year of $9.60, up 9% over 2016 Free Cash Flow: Q4 of $468 million, up 25% from 2016; Full year of $1.1 billion, up 28% over 2016 2018 Ad... 
Printer Friendly Version
01/19/18LabCorp Named to FORTUNE Magazine's 2018 List of ‘World’s Most Admired Companies’
BURLINGTON, N.C.--(BUSINESS WIRE)--Jan. 19, 2018-- Laboratory Corporation of America® Holdings (LabCorp) (NYSE: LH), a leading global life sciences company, today announced that it has been named to FORTUNE magazine's 2018 List of World’s Most Admired Companies. The annual survey, conducted by FORTUNE and the Hay Group division of Korn Ferry, a global people and organizational advisory firm, is given to top executives, directors and financial anal... 
Printer Friendly Version
01/08/18Covance Introduces Dedicated Offering Designed for Biotech, Medical Device and Diagnostics Companies
Distinctive development solutions provided by Chiltern®, a Covance® company BURLINGTON, N.C.--(BUSINESS WIRE)--Jan. 8, 2018-- LabCorp® (NYSE: LH), a leading global life sciences company, announced today that its Covance Drug Development (Covance) business has introduced a dedicated offering for biotech, medical device and diagnostics companies from Chiltern®, a Covance® company. This unique offering follows the acquisition of Chiltern, a leadi... 
Printer Friendly Version
01/03/18LabCorp is Scheduled to Present at the 36th Annual J.P. Morgan Healthcare Conference
BURLINGTON, N.C.--(BUSINESS WIRE)--Jan. 3, 2018-- LabCorp® (NYSE: LH) today announced it will participate at the 36th Annual J.P. Morgan Healthcare Conference. LabCorp’s presentation is scheduled for Tuesday, January 9, 2018 at 9:30 am (PT). A live audio webcast of the presentation will be available via the Company website at www.labcorp.com and archived for replay. About LabCorp LabCorp (NYSE: LH), an S&P 500 co... 
Printer Friendly Version
01/02/18Conversion Right Triggered For LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021
BURLINGTON, N.C.--(BUSINESS WIRE)--Jan. 2, 2018-- LabCorp® (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below. The Zero Coupon Notes are convertible into cash and Common Stock of LabCorp, if any, subject to the terms of the Zero Coupon Notes and the Indenture, dated as of October 24, 2006 between LabCorp and The Bank of New York Mellon, as trustee ... 
Printer Friendly Version
Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts | IR Contacts IR Contacts | Financial Tear Sheet Tear Sheet